Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Inclusion Criteria:

• Patients must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in SolidTumors (RECIST) v1.1 criteria.
• Patients must have had progressive disease on, after, or refused, appropriate approvedtherapy for their tumor type.
• Patients must have histologically or cytologically confirmed solid tumor that islocally recurrent or metastatic and has progressed following standard treatment or isnot appropriate for standard treatment
• Understand and sign an Institutional review board/Independent ethics committee (IRB/IEC)-approved informed consent form (ICF) prior to any study-specific evaluation
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Willing and able to comply with all study procedures

Exclusion Criteria:

• Current or history of clinically significant muscle disorders (e.g., myositis), recentunresolved muscle injury, or any condition known to elevate serum creatine kinase (CK)levels
• Decreased cardiac function with New York Heart Association (NYHA) > Class 2
• Uncontrolled or significant heart disorder such as unstable angina
• Significant abnormalities on electrocardiogram (ECG) at screening. Fridericia'scorrection formula for QT interval (QTcF) > 450 msec for males or > 470 msec forfemales at screening
• History of anti-drug antibodies, severe allergic, anaphylactic, or otherinfusion-related reaction to a previous biologic agent
• Positive test for latent tuberculosis (TB) at screening (Quantiferon test) or evidenceof active TB
• Patients with abnormal serum chemistry values, which in the opinion of theInvestigator is considered to be clinically significant, will be excluded from thestudy
• Lack of peripheral venous or central venous access or any condition that wouldinterfere with drug administration or collection of study samples
• Any uncontrolled medical condition or psychiatric disorder which, in the opinion ofthe Investigator, would pose a risk to patient safety or interfere with studyparticipation or interpretation of individual patient results
• Pregnant or breastfeeding
• Current unresolved infection or history of chronic, active, clinically significantinfection (viral, bacterial, fungal, or other) which, in the opinion of theInvestigator, would preclude the patient from exposure to a biologic agent or pose arisk to patient safety
• Prior exposure to any colony stimulating factor 1 receptor (CSF1R) pathway inhibitors